Ciphergen s Revenues Rise in Q4; Net Loss Remains Flat

Feb 17, 2004

NEW YORK, Feb. 17 (GenomeWeb News) - Ciphergen Biosystems today reported increased revenues, along with stable losses and R&D expenses, for the last quarter of 2003.

Revenues for the quarter were $15.2 million, up from $13.6 million during the same period in 2002.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

An RNAi Approval

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Keep It Going

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Stop It There

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

This Week in PLOS

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.

Main menu